Detailed Product Description

Food and Drug Administration (FDA) has granted marketing approval for Synvisc-One hylan G-F 20, a product intended for the relief of pain associated with osteoarthritis OA of the knee. Synvisc-One is the only single-injection viscosupplement approved for the treatment of OA knee pain in the United States. This therapy has the potential to redefine the market for viscosupplementation products by extending the benefits of this therapeutic approach to a broader set of patients and reducing the total cost and burden of multiple injections.

DROP SHIPPING AVAILABLE!